Skip to main content

Amyotropic Lateral Sclerosis (ALS) clinical trials at UC Irvine

8 in progress, 6 open to eligible people

Showing trials for
  • A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

    open to eligible people ages 18-80

    The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

    Orange, California and other locations

  • Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

    open to eligible people ages 18-75

    To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:

    Orange, California and other locations

  • Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

    open to eligible people ages 18-80

    A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

    Orange, California and other locations

  • HEALEY ALS Platform Trial - Master Protocol

    open to eligible people ages 18 years and up

    The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

    Orange, California and other locations

  • Intermuscular Coherence as a Biomarker for ALS

    open to eligible people ages 20-80

    The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of ALS patients longitudinally to determine if IMC-βγ changes with ALS disease progression and whether such changes correlate with functional and clinical scores, or survival.

    Irvine, California and other locations

  • Multiple Doses of AT-1501-A201 in Adults With ALS

    open to eligible people ages 18 years and up

    This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.

    Orange, California and other locations

  • Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

    Sorry, not accepting new patients

    Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for participants who completed all scheduled treatments and follow-up assessments in BCT-002-US study

    Irvine, California and other locations

  • Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

    Sorry, not currently recruiting here

    The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

    Orange, California and other locations

Last updated: